Merck Anticipates Keytruda Will Be Included in Government Price Setting by 2026

Merck has announced that it expects its leading cancer therapy, Keytruda, to be part of the government price setting initiative in 2026, with the new pricing structure set to take effect on January 1, 2028. This development comes as Merck reported that U.S. sales for Keytruda, which generated an impressive $29.48 billion in sales in 2024, are likely to decline following this regulatory change.

Keytruda has been a significant contributor to Merck's revenue, accounting for 46% of the company's total sales last year. However, the pharmaceutical giant anticipates further decreases in sales as key patents expire in 2028.

Approved in 2014, Keytruda utilizes the body’s immune system to combat various cancers, showcasing remarkable efficacy. The upcoming price negotiations are part of a broader initiative established under the Inflation Reduction Act during the Biden administration, which allows Medicare to negotiate prices for high-cost medications.

In January, the U.S. government released a list of 15 drugs targeted for Medicare price negotiations, which includes several cancer therapies. Previous negotiations saw price cuts ranging from 38% to 79% for popular prescription drugs, set to take effect in 2026.

As the pharmaceutical industry faces growing pressure to adapt to these changes, Merck's proactive stance regarding Keytruda's pricing reflects both the challenges and opportunities that lie ahead in the evolving healthcare landscape.